Cargando…

Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma

Siglec‐15, a novel immune checkpoint, is an emerging target for next‐generation cancer immunotherapy. However, the role of Siglec‐15 in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. We investigated the expression of Siglec‐15 and its association with clinicopathological characte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xianlong, Mo, Shengwei, Zhang, Yue, Ma, Heng, Lu, Zhaohui, Yu, Shuangni, Chen, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977273/ https://www.ncbi.nlm.nih.gov/pubmed/35083884 http://dx.doi.org/10.1002/cjp2.260

Ejemplares similares

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
por: Zhang, Yue, et al.
Publicado: (2022)

Intratumoral neutrophil extracellular traps are associated with unfavorable clinical outcomes and immunogenic context in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

A Novel Signature Based on m6A RNA Methylation Regulators Reveals Distinct Prognostic Subgroups and Associates with Tumor Immunity of Patients with Pancreatic Neuroendocrine Neoplasms
por: Chen, Xianlong, et al.
Publicado: (2022)

Upregulated MicroRNA-483-3p is an Early Event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a Powerful Liquid Biopsy Biomarker in PDAC
por: Shao, Huilin, et al.
Publicado: (2021)

RUNX1 promote invasiveness in pancreatic ductal adenocarcinoma through regulating miR-93
por: Cheng, Yin, et al.
Publicado: (2017)

Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma
por: Zhang, Li, et al.
Publicado: (2018)

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma
por: Loch, Florian N., et al.
Publicado: (2023)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
por: Kabacaoglu, Derya, et al.
Publicado: (2018)

Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma
por: Wu, Jiangchao, et al.
Publicado: (2022)

MiRNA-615-5p Functions as a Tumor Suppressor in Pancreatic Ductal Adenocarcinoma by Targeting AKT2
por: Sun, Yang, et al.
Publicado: (2015)

Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
por: Li, Hong-Bo, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
por: Balsano, Rita, et al.
Publicado: (2023)

Correction: MiRNA-615-5p Functions as a Tumor Suppressor in Pancreatic Ductal Adenocarcinoma by Targeting AKT2
por: Sun, Yang, et al.
Publicado: (2015)

Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma
por: Zhan, Weixiang, et al.
Publicado: (2023)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas
por: Li, Baihui, et al.
Publicado: (2023)

Gα15 in early onset of pancreatic ductal adenocarcinoma
por: Innamorati, Giulio, et al.
Publicado: (2021)

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
por: Wang, Jun, et al.
Publicado: (2019)

Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle
por: Ren, Xiubao
Publicado: (2019)

Protocol for identifying immune checkpoint on circulating tumor cells of human pancreatic ductal adenocarcinoma by single-cell RNA sequencing
por: Liu, Xiaowei, et al.
Publicado: (2023)

Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022)

Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas
por: Zong, Liju, et al.
Publicado: (2023)

Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma
por: Ito, Zensho, et al.
Publicado: (2017)

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
por: Li, Guan-Zhang, et al.
Publicado: (2019)

Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
por: Ravindranathan, Sruthi, et al.
Publicado: (2022)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023)

Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma
por: Jiang, Yongsheng, et al.
Publicado: (2023)

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
por: Zhang, Tianyi, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Proteome alterations in pancreatic ductal adenocarcinoma
por: Pan, Sheng, et al.
Publicado: (2020)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Unveiling the molecular features, relevant immune and clinical characteristics of SIGLEC15 in thyroid cancer
por: Hou, Xiaofeng, et al.
Publicado: (2022)

The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis
por: Yang, Bing, et al.
Publicado: (2021)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Ezrin promotes invasion and metastasis of pancreatic cancer cells
por: Meng, Yunxiao, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5phrkufocld9ncs8e4v78877cd